Cargando…

Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy—findings from clinical practice

PURPOSE: Clinical practice adherence to current guidelines that recommend primary prophylaxis (PP) with granulocyte colony-stimulating factors (G-CSFs) for patients at high (≥20 %) overall risk of febrile neutropenia (FN) was evaluated. METHODS: Adult patients with breast cancer, non-small cell lung...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krzemieniecki, K., Sevelda, P., Erdkamp, F., Smakal, M., Schwenkglenks, M., Puertas, J., Trojan, A., Szabo, Z., Bendall, K., Maenpaa, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913845/ https://www.ncbi.nlm.nih.gov/pubmed/24154740 http://dx.doi.org/10.1007/s00520-013-2021-2

Ejemplares similares

Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland
por: Wojtukiewicz, Marek, et al.
Publicado: (2014)

Appropriateness of granulocyte colony-stimulating factor use in patients receiving chemotherapy by febrile neutropenia risk level
por: Baig, Hassam, et al.
Publicado: (2018)

Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors
por: Kelly, S, et al.
Publicado: (2009)

Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
por: Advani, S. H., et al.
Publicado: (2010)

Outcomes for patients with severe chronic neutropenia treated with granulocyte colony-stimulating factor
por: Dale, David C., et al.
Publicado: (2022)

Granulocyte Colony-stimulating Factor for Preterms with Sepsis and Neutropenia: A Randomized Controlled Trial
por: Chaudhuri, Jasodhara, et al.
Publicado: (2012)

Meta-Analysis of Same-Day Pegfilgrastim Administration Stratified by Myelotoxic Febrile Neutropenia Risk and Tumor Type
por: Alrawashdh, Neda, et al.
Publicado: (2022)

Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice
por: Averin, Ahuva, et al.
Publicado: (2020)

Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
por: Aapro, Matti, et al.
Publicado: (2010)

Granulocyte-colony-stimulating Factor-resistant Neutropenia and Polyneuropathy Presenting as Severe Complications of Sjögren's Syndrome
por: Tomita, Katsuyuki, et al.
Publicado: (2022)

Incidence of neutropenia, chemotherapy delivery, and use of colony-stimulating factor in patients with non-Hodgkin lymphoma of different age groups
por: Pettengell, Ruth, et al.
Publicado: (2011)

Timing of recombinant human granulocyte colony-stimulating factor administration on neutropenia induced by cyclophosphamide in normal mice.
por: Misaki, M., et al.
Publicado: (1998)

Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis
por: Cooper, Katy L, et al.
Publicado: (2011)

Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?
por: Leleu, Xavier, et al.
Publicado: (2017)

Clozapine rechallenge following neutropenia using granulocyte colony-stimulating factor: A Quebec case series
por: Béchard, Laurent, et al.
Publicado: (2021)

Granulocyte Antibodies in Korean Neonates with Neutropenia
por: Han, Tae Hee, et al.
Publicado: (2006)

Autonomous production of granulocyte-colony stimulating factor in tumour xenografts associated with leukocytosis.
por: Katoh, Y., et al.
Publicado: (1993)

S1. CLOZAPINE RECHALLENGE FOLLOWING NEUTROPENIA USING GRANULOCYTE COLONY-STIMULATING FACTOR: A QUEBEC CASE SERIES
por: Béchard, Laurent, et al.
Publicado: (2020)

Evaluating the Prognostic Role of Monocytopenia in Chemotherapy-Induced Febrile Neutropenia Patients Treated with Granulocyte Colony-Stimulating Factor
por: Alshari, Osama, et al.
Publicado: (2021)

Continuous Intravenous Administration of Granulocyte-Colony-Stimulating Factors—A Breakthrough in the Treatment of Cancer Patients with Febrile Neutropenia
por: Căinap, Călin, et al.
Publicado: (2021)

Effects of primary granulocyte-colony stimulating factor prophylaxis on the incidence of febrile neutropenia in patients with germ cell tumors
por: Hapakova, Nikola, et al.
Publicado: (2022)

Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer
por: Aapro, Matti S., et al.
Publicado: (2023)

Stem cell assays in the evaluation of myelotoxicity
por: Mangalik, Aroop, et al.
Publicado: (1981)

Assessment of myelotoxicity caused by environmental chemicals.
por: Boorman, G A, et al.
Publicado: (1982)

Evaluation of Myelotoxicity in Dietary Restricted Rats
por: Miyata, Hiroto, et al.
Publicado: (2009)

The Effect of Granulocyte Colony Stimulating Factor Administration on Preterm Infant with Neutropenia and Clinical Sepsis: A Randomized Clinical Trial
por: Borjianyazdi, L, et al.
Publicado: (2013)

Systemic chemotherapy with pronounced efficacy and neutropenia in a granulocyte-colony stimulating factor-producing advanced gastric neuroendocrine carcinoma
por: Tsuruta, Nobuhiro, et al.
Publicado: (2017)

Azathioprine-induced Myelotoxicity After Switching Mesalazine Compound
por: Barnhoorn, Marieke C, et al.
Publicado: (2021)

Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma
por: Pettengell, Ruth, et al.
Publicado: (2011)

Analytical approaches to the study of the disposition of myelotoxic agents.
por: Rickert, D E, et al.
Publicado: (1981)

Erratum to: Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma
por: Pettengell, Ruth, et al.
Publicado: (2012)

A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia
por: Clemons, Mark, et al.
Publicado: (2021)

The Effect of Recombinant Granulocyte Colony-Stimulating Factor on Oral and Periodontal Manifestations in a Patient with Cyclic Neutropenia: A Case Report
por: Matarasso, Sergio, et al.
Publicado: (2009)

Risk of chemotherapy-induced febrile neutropenia in intermediate-risk regimens: Clinical and economic outcomes of granulocyte colony-stimulating factor prophylaxis
por: Aslam, Saad, et al.
Publicado: (2023)

Patterns of granulocyte colony–stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy
por: Gawade, Prasad L., et al.
Publicado: (2020)

Genetic differences in susceptibility to chemically induced myelotoxicity and leukemia.
por: Nebert, D W
Publicado: (1981)

Azathioprine: Tuberculous perihepatic abscess and myelotoxicity: case report
Publicado: (2021)

Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain – results of the LEARN Study
por: ALMENAR, D, et al.
Publicado: (2009)

Systematic Review and Meta-analysis of Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia
por: Cornes, Paul, et al.
Publicado: (2018)

Eflapegrastim, a Long‐Acting Granulocyte‐Colony Stimulating Factor for the Management of Chemotherapy‐Induced Neutropenia: Results of a Phase III Trial
por: Schwartzberg, Lee S., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_57j54is3e5g4js44c4re8ulujn